

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (10/25/20)  
**Date:** Sunday, October 25, 2020 9:52:18 AM  
**Attachments:** [Funding02.PNG](#)

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.



## Research Awards & Funding Opportunities

Dear Research Community,

Below are COVID-19 funding opportunities recently released from the funding opportunity database SPIN.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100403	<a href="#">Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)</a>	National Center for Advancing Translational Sciences/NIH/DHHS	NOT-TR-21-006	Continuous Submission	Not Specified

Contact Name: Bobbie Ann Mount, Ph.D.  
Contact Telephone: 301-435-0824  
Contact Email: [newtherapeuticuses@mail.nih.gov](mailto:newtherapeuticuses@mail.nih.gov)  
Sponsor Website:  
Program URL: [Link to program URL](#)  
Deadline Dates (ALL)

NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-

Synopsis

CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

098065	<a href="#">RFA-OH-21-004 -- Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)</a>	National Institute for Occupational Safety & Health/CDC/DHHS	RFA-OH-21-004	06-Nov-2020 [Optional] [LOI/Pre-App]	500,000 USD
--------	--	--	---------------	--------------------------------------	-------------

Contact Name James Yiin, PhD, Scientific Program Official

Contact Telephone 513-841-4271

Contact Email [JYiin@cdc.gov](mailto:JYiin@cdc.gov)

Sponsor Website

Program URL [Link to program URL](#)

Deadline Dates (ALL) 06-Nov-2020 [Optional][LOI/Pre-App], 08-Dec-2020

Synopsis

NIOSH supports exploratory and developmental research projects (R21) that address/mitigate/improve issues related to diagnostic or treatment uncertainty with respect to individuals, including enrolled World Trade Center (WTC) responders and certified-eligible WTC survivors, receiving monitoring and/or treatment under subtitle B, of the James Zadroga 9/11 health and Compensation Act (Public Law 111-347). NIOSH seeks to achieve a suitable mix of projects that help advance treatment and diagnostic effectiveness and the understanding of the health and well-being of the WTC Health Program members related to the September 2001 terrorist attacks. This FOA invites applications from both experienced researchers and researchers who are at the early stage of their independent careers or have not had substantial prior NIH/CDC funding. Importantly, applicants are expected to propose research approaches for which there are minimal or no preliminary data.

NOTE: Per NOT-OH-021-002 the research scope of this FOA allows submission of COVID-related research proposals on individuals exposed to the September 2001 terrorist attacks, including responders and community members (also referred to as survivors). For the requirement to include the primary diseases or conditions listed in Section I of the FOA that you propose to study, please use "emerging conditions" for COVID-19.

---

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

[Visit the Research Portal Getting Started page](#) and enter email address under **Research Listserv** to update your subscription preferences at any time within the MSHS firewall.